DeCarolis et al.

(19)

190 mixed (UP & BP) depressed

inpatients (109 psychotic)

Imipramine (200-350 mg/day)

for 30 days; crossover, ECT

(8-10 treatments), open

trial

72% ECT response rate

(proportions not

reported)

Medical Research

Council (59)

250 depressed inpatients

Medication failures (IMI or

phenelzine), crossover ECT

(4-8 treatments), open trial

50% response in TRD

versus 71% in

nonresistant patients

(proportions not

reported)

Mandel et al. (57)

76 TCA-resistant or TCA-

intolerant depressed inpatients

Retrospective review of 100

charts yielded 76 TCA

resistant cases (IMI @ 150

mg/day {ewc MVIMG, MVIMAGE,!times.bmp} 3 weeks); open

trial

54 of 76 (71 %) ECT

responders

Paul et al. (73)

9 medication-resistant inpatients

Adequate pharmacotherapy;

open trial

8 of 9 (89%) ECT

responders

Hamilton (41)

146 melancholic inpatients

Medication failure or intolerant

to either IMI or phenelzine;

open trial

82 of 146 (68%)

responders

Magni et al. (56)

28 medication-resistant patients

Adequate pharmacotherapy;

Open trial

17 of 28 (61%)

responders

Prudic et al. (84)

24 depressed inpatients (6

psychotic)

IMI (or equivalent) {ewc MVIMG, MVIMAGE,!greateq.bmp} 200 mg

{ewc MVIMG, MVIMAGE,!times.bmp} 4 wks, Open trial

TRD 12 of 24 (50%)

ECT responders

non TRD: 24 of 29

(86%) ECT

responders

Dinan and Barry

(25)

15 depressed inpatients

AMI (or equivalent) 175 mg;

Randomized trial (versus Li

augmentation, n = 15); 6

bilat. ECT

ECT: 11 of 15 (73%)

responders

Li : 10 of 15 (67%)

responders